Log in

NASDAQ:IMUXImmunic Stock Price, Forecast & News

$12.27
-0.42 (-3.31 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.05
Now: $12.27
$12.64
50-Day Range
$9.76
MA: $12.35
$15.86
52-Week Range
$4.19
Now: $12.27
$19.05
Volume151,400 shs
Average Volume373,595 shs
Market Capitalization$183.68 million
P/E RatioN/A
Dividend YieldN/A
Beta3.17
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMUX
CUSIPN/A
CIKN/A
Phone332-255-9818

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.77 per share

Profitability

Net Income$-34,930,000.00

Miscellaneous

EmployeesN/A
Market Cap$183.68 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive IMUX News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.

Immunic (NASDAQ:IMUX) Frequently Asked Questions

How has Immunic's stock been impacted by COVID-19 (Coronavirus)?

Immunic's stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMUX shares have increased by 58.3% and is now trading at $12.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Immunic?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunic.

When is Immunic's next earnings date?

Immunic is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Immunic.

How were Immunic's earnings last quarter?

Immunic (NASDAQ:IMUX) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.96) by $0.17. View Immunic's earnings history.

What price target have analysts set for IMUX?

4 brokers have issued 12 month target prices for Immunic's shares. Their forecasts range from $40.00 to $58.00. On average, they anticipate Immunic's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 281.0% from the stock's current price. View analysts' price targets for Immunic.

Has Immunic been receiving favorable news coverage?

News stories about IMUX stock have been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunic earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Immunic.

Are investors shorting Immunic?

Immunic saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 57,800 shares, a decrease of 11.5% from the June 15th total of 65,300 shares. Based on an average daily trading volume, of 285,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.9% of the shares of the company are sold short. View Immunic's Current Options Chain.

Who are some of Immunic's key competitors?

What other stocks do shareholders of Immunic own?

Who are Immunic's key executives?

Immunic's management team includes the following people:
  • Dr. Daniel Vitt, CEO, Pres & Director (Age 51)
  • Dr. Manfred Gröppel, Co-Founder & COO
  • Dr. Andreas Mühler Ph.D., Co-Founder and Chief Medical Officer (Age 56)
  • Ms. Tamara A. Seymour, Interim Chief Financial Officer (Age 60)
  • Dr. Hella Kohlhof, Chief Scientific Officer

What is Immunic's stock symbol?

Immunic trades on the NASDAQ under the ticker symbol "IMUX."

How do I buy shares of Immunic?

Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunic's stock price today?

One share of IMUX stock can currently be purchased for approximately $12.27.

How big of a company is Immunic?

Immunic has a market capitalization of $183.68 million. The company earns $-34,930,000.00 in net income (profit) each year or ($4.52) on an earnings per share basis.

What is Immunic's official website?

The official website for Immunic is www.immunic-therapeutics.com.

How can I contact Immunic?

Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The company can be reached via phone at 332-255-9818 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.